May 21, 2019 – Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that Accipio Ax will begin shipping in August and will be available as the second part of the Accipio ICH Platform. Accipio Ax will provide new tools to support clinical assessment of intracranial hemorrhage (ICH). Radiology departments, emergency room and neuroradiology teams across the U.S. and the EU will soon be able to access a comprehensive solution for ICH triage through workflow prioritization and slice-level preview. Accipio Ax includes the exclusive Accipio Ax SliceMap, an integrated view which guides clinicians rapidly to computed tomography (CT) slices with suspected ICH without leaving their picture archiving and communication system (PACS) viewer.
With regulatory approvals and a U.S. Food and Drug Administration (FDA) Breakthrough Device designation for Accipio Dx – MaxQ AI’s Accipio suite of software is a fully-automated solution integrated by major original equipment manufacturer (OEM) CT, PACS and AI ecosystem partners. With the potential for improving detection and workflow for suspected ICH, these solutions enable faster and more accurate treatment of patients.
“Each month Accipio Ix processes nearly 1,000 head CT scans, including upwards of 30 stroke cases per week, at Capital Health,” said Ajay Choudhri, M.D., chairman of the Department of Radiology at Capital Health Hospitals in New Jersey. “With Accipio Ax, we can now benefit from a comprehensive solution for triage through workflow prioritization and slice-level preview of ICH, including the exclusive Accipio Ax SliceMap, which guides users rapidly to CT images with suspected ICH.”
With less money than ever before and a shortage of healthcare providers attempting to serve a growing number of patients, medical diagnostic AI solutions have the potential to fill a critical void within the healthcare system. It is projected that there will be 3.4 million stroke victims by 2030, which will cause loss or extreme hardships for patients and their families, while generating $240 billion in total direct and indirect costs.1
The Accipio ICH Platform, the complete ICH solution for stroke and head trauma assessment, promises to help address this by greatly increasing intracranial hemorrhage (ICH) detection and reducing missed ICH through near real-time triage, annotation and diagnostic rule-out.
MaxQ AI is demonstrating the full suite of Accipio ICH Platform solutions during the 57th American Society of Neuroradiology (ASNR) Annual Meeting, May 18-23 in Boston.
For more information: www.maxq.ai
Related Content
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
MaxQ AI's Accipio Software Integrated to GE's Smart Subscription Platform
VIDEO: How Artificial Intelligence Can Detect Brain Bleeds
Reference
1. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke. 2013 Aug;44(8):2361-75. doi: 10.1161/STR.0b013e31829734f2
August 13, 2025 
